Semaglutide for Cardiovascular Event Reduction in People With Overweight or Obesity
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics
Obesity 2023 Jan 01;31(1)111-122, I Lingvay, K Brown-Frandsen, HM Colhoun, J Deanfield, SS Emerson, S Esbjerg, S Hardt-Lindberg, GK Hovingh, SE Kahn, RF Kushner, AM Lincoff, SP Marso, TM Fries, J Plutzky, DH RyanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.